Mark Pruzanski, CEO & President at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 80,000 shares at $129.49 ($10.5M) on 2017-06-26, disclosed to the SEC on 2017-06-28.
Seasonal sale ($10.5M) by CEO & President — this insider has traded ICPT in June in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $129.49 | 7,816 | $1.0M | 9.7% |
| 2 | $129.49 | 7,816 | $1.0M | 9.7% |
| 3 | $130.46 | 18,763 | $2.4M | 23.4% |
| 4 | $130.46 | 18,763 | $2.4M | 23.4% |
| 5 | $131.18 | 5,893 | $773K | 7.4% |
| 6 | $131.18 | 5,893 |
| $773K |
| 7.4% |
| 7 | $132.54 | 5,485 | $727K | 6.9% |
| 8 | $132.54 | 5,485 | $727K | 6.9% |
| 9 | $133.07 | 2,043 | $272K | 2.6% |
| 10 | $133.07 | 2,043 | $272K | 2.6% |
| Total | $130.80 avg | 80,000 | $10.5M | 100% |
| Filing → |
| ICPT | SELL | 2019-11-27 | $5.0M | — | Filing → |
| ICPT | SELL | 2018-11-16 | $9.1M | — | Filing → |
| ICPT | BUY | 2018-04-09 | $500K | — | Filing → |